FOUND: 23 - You Need To See This

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Barchart · Apr 10, 2024

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com · Apr 5, 2024

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK · Mar 28, 2024

FDA approves Wegovy for lowering heart attack and stroke risk in overweight patients

The popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.

WEKU · Mar 8, 2024

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

International Business Times · Mar 8, 2024

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

FDA approves Wegovy label change to reduce cardiovascular risk in overweight patients, a significant advancement in obesity treatment with potential implic...

Top News · Mar 8, 2024

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Barchart · Mar 8, 2024

Novo Nordisk CEO Warns Of Health Risks From Semaglutide

Novo Nordisk CEO addresses concerns about compounded semaglutide for diabetes and obesity, emphasizing safety risks and need for FDA-approved medications.

Top News · Mar 8, 2024

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Barchart · Feb 28, 2024

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times · Feb 28, 2024